Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
London has made a cautious start to the day with miners weak though a burst of M&A has lifted the mood elsewhere. Mining giants BHP Billiton and Rio Tinto have confirmed that their proposed $116bn Pilbara iron ore joint venture is dead in the water. The companies had agreed in December of last ye
Read moreJordan-based pharmaceuticals firm Hikma has sorted out its dispute with Mutual Pharmaceutical relating to the sale of oral colchicine tablets. Hikma's subsidiary and US agent, West-Ward Pharmaceutical, has discontinued its sales of oral colchicine until approval of its New Drug Application by the U
Read moreThe last quarter of 2010 started well for London's leading share index, with buoyancy in the oil sector helping to offset continuing economic worries at home and abroad. Manufacturing data was subdued. Footsie gave up some of its early gains after figures from the US showed Manufacturing grew at th
Read moreThe afternoon session has seen the Footsie advance confidently, almost regaining its high for the day which was hit shortly after 10:00am. A solid start by Wall Street on the back of better than expected spending data has helped sentiment this side of the pond. Oil giant BP is higher amid speculat
Read moreSome investors may be bailing on pharmaceuticals firm Hikma in the wake of the press speculation about a plan by US regulators to ban unapproved oral colchicine products to treat gout, but Panmure Gordon is sticking by the stock. "We note the company's announcement this morning regarding the seemin
Read moreSome investors may be bailing on pharmaceuticals firm Hikma in the wake of the press speculation about a plan by US regulators to ban unapproved oral colchicine products to treat gout, but Panmure Gordon is sticking by the stock. "We note the company's announcement this morning regarding the seemin
Read moreLondon's leading share index remains in positive territory, but worries over the European debt situation have weighed on sentiment slightly. The concerns centre on Ireland again, after figures showed manufacturing activity in the country contracted in September, with the purchasing managers' index
Read moreShares have got off to a strong start on the first day of the last quarter, with oil stocks setting the pace. BP is higher amid speculation that dividends will soon be resumed. Bob Dudley, who becomes chief executive of the oil company today, said that the board would meet soon to discuss restoring
Read moreLondon looks set to start the final quarter of 2010 in positive mood with sentiment lifted by hints from the incoming boss of oil giant BP that the company is ready to restore dividend payments that were suspended during the Gulf of Mexico crisis. Bob Dudley, who becomes chief executive of the oil
Read moreDrugs group Hikma Pharmaceuticals has moved to calm fears about the impact of a plan by US regulators to ban unapproved oral colchicine products to treat gout. Its shares tumbled yesterday on the news. Investors also worried about comments from Numis analyst Jonathan Kwok that August's impressive i
Read moreStocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 0717 GMT [Dow Jones] JPMorgan Cazenove initiates Hikma Pharmaceuticals (HIK.LN) at overweight with 870p target, citing lea
Read more0717 GMT [Dow Jones] JPMorgan Cazenove initiates Hikma Pharmaceuticals (HIK.LN) at overweight with 870p target, citing leading long-term growth and the potential for a near-term EPS beat. Notes Hikma's competitive advantages as the top local player in the Middle East & North Africa pharmaceutical ma
Read moreBroker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 0653 GMT [Dow Jones] Royal Bank of Scotland initiates coverage on Hikma Pharmaceuticals (HIK.LN), with a hold rating and 750p
Read more0653 GMT [Dow Jones] Royal Bank of Scotland initiates coverage on Hikma Pharmaceuticals (HIK.LN), with a hold rating and 750p target price. "Our optimistic forecasts reflect Hikma's strong position in MENA [Middle East and North Africa] and its strategy of globalizing the platform, which should allo
Read moreStocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 0816 GMT [Dow Jones] UBS raises Hikma Pharmaceuticals (HIK.LN) price target to 770p from 715p to adjust for current FX rat
Read more
Last checked at